Bayer announced plans to acquire two investigational imaging agents from Attralus, a clinical-stage biopharmaceutical company, on January 12th, 2026. Both agents are being investigated as diagnostic tools for cardiac amyloidosis, a spectrum of diseases caused by the abnormal build-up of amyloid in the heart tissue. Financial details of the transaction were not disclosed in the press release announcing the acquisitions.
AT-01 (124-Iodine-evuzamitide) is a non-invasive pan-amyloid positron emission tomography imaging agent currently in Phase III development. According to the release, it is one of the first investigational diagnostic image agents to receive a Breakthrough Therapy Designation from FDA, which it received in August 2024. AT-01 also received Orphan Drug Designations from both FDA and EMA in December 2022. AT-05 (PAR-Peptide + technetium-99m) is a single photon emission computed tomography tracer currently in Phase I development.
“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy,” said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President, Pharmaceuticals Division, Bayer, in the release. “AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes – a clear extension of our commitment to tackling cardiovascular disease and addressing significant unmet needs.”
“We are excited to finalize this agreement with Bayer, whose expertise and global footprint in radiology will help to accelerate the development and launch of AT-01 and AT-05, our two novel diagnostic imaging agents for systemic amyloidosis,” said Glen Firestone, President, Attralus, in the release. “Despite recent progress in systemic amyloidosis, most patients continue to remain undiagnosed or are diagnosed too late in their disease progression. Consistent with Attralus’ mission, we believe that these pan-amyloid imaging agents will enable earlier diagnosis and treatment, leading to improved patient outcomes. Bayer’s commitment to scientific rigor and patient impact makes them well-suited to bring these agents to clinicians and patients worldwide. Attralus will now focus on advancing its innovative pan-amyloid removal therapeutics, with AT-02 in Phase II and next generation candidates in preclinical development.”
“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level,” said Nelson Ambrogio, President, Radiology, Bayer, in the release. “This acquisition marks our entry into diagnostic tracers. Leveraging our expertise in medical imaging – including our pipeline and portfolio in advanced fluid delivery devices for nuclear medicine – it supports our ambition to expand in the growing field of molecular imaging. Building on Attralus’ research and development expertise, we will further advance scientific progress with the aim to broaden diagnostic options and make a meaningful difference for people living with cardiac amyloidosis.”
